Arthur  Tzianabos net worth and biography

Arthur Tzianabos Biography and Net Worth

Arthur Tzianabos, Ph.D., brings 25 years of experience in the biotechnology industry leading teams in the discovery, development, clinical translation and commercialization of new treatments for rare diseases. During his nine-year tenure at Shire, Dr. Tzianabos had an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire’s pipeline. Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He is Chairman of the Board for Akouos Therapeutics, a member of the Board of Directors for Stoke Therapeutics, serves on the Development Board for the University of New Hampshire’s College of Life Sciences and Agriculture and is a member of the Alliance for Regenerative Medicine’s Board of Directors and Executive Committee. He has published more than 80 scientific papers, reviews, book chapters and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.

What is Arthur Tzianabos' net worth?

The estimated net worth of Arthur Tzianabos is at least $0.00 as of January 9th, 2024. Dr. Tzianabos owns 257,556 shares of Homology Medicines stock worth more than $0 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. Tzianabos may own. Learn More about Arthur Tzianabos' net worth.

How do I contact Arthur Tzianabos?

The corporate mailing address for Dr. Tzianabos and other Homology Medicines executives is ONE PATRIOTS PARK, BEDFORD MA, 01730. Homology Medicines can also be reached via phone at (781) 301-7277 and via email at [email protected]. Learn More on Arthur Tzianabos' contact information.

Has Arthur Tzianabos been buying or selling shares of Homology Medicines?

During the last quarter, Arthur Tzianabos has sold $7,431.09 of Homology Medicines stock. Most recently, Arthur Tzianabos sold 26,074 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $0.2850, for a transaction totalling $7,431.09. Following the completion of the sale, the director now directly owns 257,556 shares of the company's stock, valued at $73,403.46. Learn More on Arthur Tzianabos' trading history.

Who are Homology Medicines' active insiders?

Homology Medicines' insider roster includes Timothy Kelly (Insider), Albert Seymour (Insider), W. Smith (CFO), and Arthur Tzianabos (CEO). Learn More on Homology Medicines' active insiders.

Are insiders buying or selling shares of Homology Medicines?

During the last twelve months, insiders at the sold shares 4 times. They sold a total of 43,728 shares worth more than $13,375.58. The most recent insider tranaction occured on January, 9th when Director Arthur Tzianabos sold 26,074 shares worth more than $7,431.09. Insiders at Homology Medicines own 16.1% of the company. Learn More about insider trades at Homology Medicines.

Information on this page was last updated on 1/9/2024.

Arthur Tzianabos Insider Trading History at Homology Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2024Sell26,074$0.29$7,431.09257,556View SEC Filing Icon  
1/9/2023Sell21,232$0.70$14,756.24216,790View SEC Filing Icon  
1/5/2022Sell10,708$1.89$20,238.12View SEC Filing Icon  
1/2/2020Sell25,000$10.25$256,250.00180,010View SEC Filing Icon  
12/2/2019Sell25,000$8.13$203,125.00230,010View SEC Filing Icon  
11/29/2019Sell25,000$8.02$200,500.00230,010View SEC Filing Icon  
10/1/2019Sell25,000$8.70$217,500.00
9/3/2019Sell25,000$9.38$234,375.00280,010View SEC Filing Icon  
8/1/2019Sell25,000$8.69$217,125.00305,010View SEC Filing Icon  
7/1/2019Sell25,000$9.49$237,250.00View SEC Filing Icon  
6/3/2019Sell25,000$9.93$248,250.00View SEC Filing Icon  
See Full Table

Arthur Tzianabos Buying and Selling Activity at Homology Medicines

This chart shows Arthur Tzianabos's buying and selling at Homology Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Homology Medicines Company Overview

Homology Medicines logo
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.44
Low: $0.29
High: $0.93

2 Week Range

Now: N/A

Volume

401,467 shs

Average Volume

249,289 shs

Market Capitalization

$54.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A